Zhejiang Haisen Pharmaceutical Co., Ltd.

Founded in 1998, Zhejiang Haisen Pharmaceutical Co., Ltd. is a company professionally engaged in researching, developing, producing and selling chemical APIs and intermediates, and the largest manufacturer of Sucralfate API. Its main products include Escitalopram Oxalate, Atorvastatin Calcium and Sodium Metamizole. Highly focused on technological innovation, the company adheres to an innovative development philosophy, continually transforming and upgrading through technology; it listed on the Shenzhen Stock Exchange in April 2023 under stock code 001367.